While TASIGNA® and GLIVEC® are both generally well tolerated, as with all treatments there are risks of adverse events. Management may not be possible in all patients—some patients may require dose adjustment, interruption, or discontinuation. The following management tips are provided for your consideration, to help with the management of some common side effects that have been associated with either TASIGNA® or GLIVEC®. For additional information, please click here to view the European SMPCs.